Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
L-fucose isomerase is an enzyme (EC 5.3.1.25) that catalyzes the reversible isomerization of the aldose L-fucose into the ketose L-fuculose as part of the L-fucose catabolic pathway in bacteria such as *Escherichia coli*. It is a manganese-dependent enzyme, typically functioning as a homohexamer with a large, unique structure distinct from other known ketol isomerases[1][3][5]. Although closely homologous enzymes exist in other bacteria and may vary slightly in substrate specificity, the canonical catalytic activity involves migration of hydrogen atoms via an ene-diol intermediate. This enzyme is notable for its role in microbial utilization of fucose, a common sugar in host glycoproteins, and is being investigated for industrial and biotechnological applications in rare sugar synthesis[7]. It is not a current therapeutic target for human drugs and has no known direct clinical safety or biomarker applications.
Catalyzes the reversible isomerization of L-fucose (aldose) to L-fuculose (ketose) via an ene-diol mechanism, requiring Mn2+ as a cofactor[1][5][7]\n- Can isomerize D-arabinose to D-ribulose in some species[2][4][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-fucose isomerase.